Can microRNAs improve the management of lung cancer patients? A clinician's perspective

Theranostics

Volumn 3, Issue 12, 2013, Pages 953-963

  Tufman, Amanda ^a   Tian, Fei ^a   Huber, Rudolf Maria ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biomarker; Early detection; Lung cancer; Microrna; Predictive marker; Prognostic marker; Screening; Thoracic oncology; Tumor biology

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; MICRORNA; NAVELBINE; PACLITAXEL; PEMETREXED; PROTEIN P53;

BLEEDING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; DISEASE COURSE; DOWN REGULATION; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; HISTOLOGY; HUMAN; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR BIOLOGY; NONHUMAN; P53 GENE; PROGNOSIS; REVIEW; SARCOMA; SMOKING; TREATMENT RESPONSE; UPREGULATION; DIAGNOSTIC USE; LUNG NEOPLASMS; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; PROCEDURES;

HUMANS; LUNG NEOPLASMS; MICRORNAS; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY;

EID: 84901201909     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.6615     Document Type: Review

References (81)

1. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2013. Ann Oncol. 2013 Mar;24(3):792-800. PubMed PMID: 23402763. Epub 2013/02/14.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2095-128. PubMed PMID: 23245604. Epub 2012/12/19.
3. Alberg A, Ford J, Samet J. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132:29S-55S. PubMed PMID: doi:10.1378/chest.07-1347.
4. Piperi C, Vlastos F, Farmaki E, Martinet N, Papavassiliou AG. Epigenetic effects of lung cancer predisposing factors impact on clinical diagnosis and prognosis. Journal of cellular and molecular medicine. 2008; 12(5a):1495-501. PubMed PMID: 18363846. Epub 2008/03/28.
5. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 2008; 26(21):3543-51.
6. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy. Journal of Clinical Oncology. 2004;22(9):1589-97.
7. Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, et al. Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non-Small-Cell Lung Cancer Treated With Carboplatin and Paclitaxel Plus Bevacizumab. Journal of Clinical Oncology., 2009; 27(9):1405-12.
8. Subramanian J, Govindan R. Lung Cancer in Never Smokers: A Review. Journal of Clinical Oncology. 2007; 25(5):561-70.
9. Becker-Santos DD, Vucic EA, Lam S, Lam WL, Martinez VD. Abstract B15: Genomic and epigenomic events in arsenic-related lung squamous cell carcinomas from smokers and never smokers. Clinical Cancer Research. 2012;18(3 Supplement):B15.
10. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. The Lancet. 2009; 374(9699):1432-40.
11. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis. Journal of the National Cancer Institute. 2007;99(11):847-57.
12. Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20, 2004; 350(21):2129-39.
13. Kris MG, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Aronson SL, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). ASCO Meeting Abstracts. 2011;29(18 suppl):CRA7506.
14. Hammerman P, Hayes D, Wilkerson M, Schultz N, Bose R, Chu A, et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 September 27, 2012;489(7417):519-25.
15. Berghmans T, Paesmans M, Sculier JP. Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol. 2011 May; 3(3):127-38. PubMed PMID: 21904576. Pubmed Central PMCID: Pmc3150064. Epub 2011/09/10.
16. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 Feb; 6(2):244-85. PubMed PMID: 21252716. Epub 2011/01/22.
17. Scoccianti C, Vesin A, Martel G, Olivier M, Brambilla E, Timsit JF, et al. Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort. Eur Respir J. 2012 Jul; 40(1):177-84. PubMed PMID: 22267755. Epub 2012/01/24.
18. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist. 2009 Mar; 14(3):253-63. PubMed PMID: 19221167. Epub 2009/02/18.
19. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3; 361(10):947-57. PubMed PMID: 19692680. Epub 2009/08/21.
20. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar; 13(3):239-46. PubMed PMID: 22285168. Epub 2012/01/31.
21. Kim D-W, Ahn M-J, Shi Y, De Pas TM, Yang P-C, Riely GJ, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts. 2012; 30(15_suppl):7533-.
22. Eismann U, Oberschmidt O, Ehnert M, Fleeth J, Ludtke F, Struck S, et al. Thymidylate synthase gene expression in solid tumors predicts for response to pemetrexed in vitro. ASCO Meeting Abstracts. 2006; 24(18_suppl):13058.
23. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006 Sep 7; 355(10):983-91. PubMed PMID: 16957145. Epub 2006/09/08.
24. Friboulet L, Olaussen KA, Pignon J-P, Shepherd FA, Tsao M-S, Graziano S, et al. ERCC1 Isoform Expression and DNA Repair in Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2013; 368(12):1101-10. PubMed PMID: 23514287.
25. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4; 365(5):395-409. PubMed PMID: 21714641. Epub 2011/07/01.
26. AMBROS V, BARTEL B, BARTEL DP, BURGE CB, CARRINGTON JC, CHEN X, et al. A uniform system for microRNA annotation. RNA. 2003; 9(3):277-9.
27. Grimson A. A targeted approach to miRNA target identification. Nat Methods. 2010; 7(10):795-7.
28. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003; 113(6):673-6.
29. Duncavage E, Goodgame B, Sezhiyan A, Govindan R, Pfeifer J. Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2010; 5(11):1755-63 10.097/JTO.0b013e3181f909d.
30. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. The microRNA spectrum in 12 body fluids. Clinical chemistry. 2010 Nov; 56(11):1733-41. PubMed PMID: 20847327. Epub 2010/09/18.
31. Molina-Pinelo S, Suarez R, Pastor MD, Nogal A, Marquez-Martin E, Martin-Juan J, et al. Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies. Disease markers. 2012;32(4):221-30. PubMed PMID: 22430188. Epub 2012/03/21.
32. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences. 2002; 99(24):15524-9.
33. Esquela-Kerscher A, Slack FJ. Oncomirs [mdash] microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259-69.
34. Iorio M, Croce C. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012 March 1, 2012;4(3):143-59.
35. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(39):13944-9.
36. Lin PY, Yu SL, Yang PC. MicroRNA in lung cancer. Br J Cancer. 2010.
37. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005 Sep 1; 23(25):5900-9. PubMed PMID: 16043828. Epub 2005/07/27.
38. Huncharek M, Muscat J, Geschwind J-F. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis. 1999; 20(8):1507-10.
39. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS Is Regulated by the let-7 MicroRNA Family. Cell. 2005; 120(5):635-47.
40. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7 microRNA Complementary Site in the KRAS 3′ Untranslated Region Increases Non-Small Cell Lung Cancer Risk. Cancer Research. 2008; 68(20):8535-40.
41. Wang R, Wang ZX, Yang JS, Pan X, De W, Chen LB. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene. 2011; 30(23):2644-58.
42. Takahashi T, Nau M, Chiba I, Birrer M, Rosenberg R, Vinocour M, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989; 246(4929):491-4.
43. Ding L, Getz G, Wheeler D, Mardis E, McLellan M, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455(7216):1069-75.
44. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007; 26(5):731-43.
45. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007; 447(7148):1130-4.
46. Chang T-C, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee Kwang H, et al. Transactivation of miR-34a by p53 Broadly Influences Gene Expression and Promotes Apoptosis. Molecular cell. 2007; 26(5):745-52.
47. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c Are Targets of p53 and Cooperate in Control of Cell Proliferation and Adhesion-Independent Growth. Cancer Research. 2007; 67(18):8433-8.
48. Jiang L, Huang Q, Chang J, Wang E, Qiu X. MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells. Experimental Lung Research. 2011;37(7):387-98. PubMed PMID: 21777146.
49. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival. Cancer Research. 2004; 64(11):3753-6.
50. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proceedings of the National Academy of Sciences. 2008; 105(10):3903-8.
51. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer cell. 2006; 9(3):189-98.
52. Yu S, Chen H, Chang G, Chen C, Chen H, Singh S, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008;13(1):48-57.
53. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. Evaluation of MicroRNA Expression Profiles That May Predict Recurrence of Localized Stage I Non-Small Cell Lung Cancer after Surgical Resection. Cancer Research. 2010;70(1):36-45.
54. Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K, et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Science. 2005; 96(2):111-5.
55. Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, Saito M, et al. MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non-Small Cell Lung Carcinoma. Cancer Research. 2010;70(21):8288-98.
56. Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, et al. MicroRNA Expression Differentiates Histology and Predicts Survival of Lung Cancer. Clinical Cancer Research. 2010;16(2):430-41.
57. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, et al. MicroRNA Classifiers for Predicting Prognosis of Squamous Cell Lung Cancer. Cancer Research. 2009; 69(14):5776-83.
58. Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, Horikawa I, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proceedings of the National Academy of Sciences. 2009;106(29):12085-90.
59. Mascaux C, Laes JF, Anthoine G, Haller A, Ninane V, Burny A, et al. Evolution of microRNA expression during human bronchial squamous carcinogenesis. European Respiratory Journal. 2009 February 1, 2009;33(2):352-9.
60. Heegaard N, Schetter A, Welsh J, Yoneda M, Bowman E, Harris C. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer. 2012 March 15, 2012;130(6):1378-86.
61. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proceedings of the National Academy of Sciences. 2011 March 1, 2011;108(9):3713-8.
62. Pastorino U, Bellomi M, Landoni C, De Fiori E, Arnaldi P, Picchio M, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet. 2003 August 23, 2003;362(9384):593-7.
63. Boeri M, Pastorino U, Sozzi G. Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer J. 2012; 18(3):268-74.
64. Bahce I, Smit EF, Lubberink M, van der Veldt AAM, Yaqub M, Windhorst AD, et al. Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status. Clinical Cancer Research. 2013; 19(1):183-93.
65. Kato Y, Miyaki S, Yokoyama S, Omori S, Inoue A, Horiuchi M, et al. Real-time functional imaging for monitoring miR-133 during myogenic differentiation. Int J Biochem Cell Biol. 2009; 41(11):2225-31.
66. Lee JY, Kim S, Hwang DW, Jeong JM, Chung J-K, Lee MC, et al. Development of a Dual-Luciferase Reporter System for In Vivo Visualization of MicroRNA Biogenesis and Posttranscriptional Regulation. Journal of Nuclear Medicine. 2008; 49(2):285-94.
67. Wang F, Niu G, Chen X, Cao F. Molecular imaging of microRNAs. Eur J Nucl Med Mol Imaging. 2011; 38(8):1572-9.
68. Krutzfeldt J, Rajewsky N, Braich R, Rajeev K, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature. 2005; 438(7068):685-9.
69. Elmén J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Research. 2008; 36(4):1153-62.
70. Hossain A, Kuo MT, Saunders GF. Mir-17-5p Regulates Breast Cancer Cell Proliferation by Inhibiting Translation of AIB1 mRNA. Molecular and Cellular Biology. 2006; 26(21):8191-201.
71. Rossbach M. Therapeutic implications of microRNAs in human cancer. Journal of Nucleic Acids Investigation. 2011; 2:e3(1):17-22.
72. Pisters KM, Le Chevalier T. Adjuvant chemotherapy in completely resected non-small-cell lung cancer. J Clin Oncol. 2005 May 10; 23(14):3270-8. PubMed PMID: 15886314. Epub 2005/05/12.
73. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008 Jul 20; 26(21):3552-9. PubMed PMID: 18506026. Epub 2008/05/29.
74. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010; 12(3):247-56.
75. Schoof C, Botelho E, Izzotti A, Vasques LR. MicroRNAs in cancer treatment and prognosis. Am J Cancer Res. 2012; 2(4):414-33.
76. Wang Q, Zhong M, Liu W, Li J, Huang J, Zheng L. Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res. 2011 Sep; 37(7):427-34. PubMed PMID: 21787234. Epub 2011/07/27.
77. Zhang X, Zhu J, Xing R, Tie Y, Fu H, Zheng X, et al. miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. Lung Cancer. 2012 September 1, 2012; 77(3):488-94.
78. Lee Y, Oh J, Yoon S, Kwon M, Song C, Kim K, et al. Differential gene expression profiles of radioresistant non-small-cell lung cancer cell lines established by fractionated irradiation: tumor protein p53-inducible protein 3 confers sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys. 2010; 77(3):858-66.
79. Kraus A, Ferber I, Bachmann S, Specht H, Wimmel A, Gross M, et al. In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene. 2002; 21(57):8683-95.
80. Lynam-Lennon N, Reynolds J, Marignol L, Sheils O, Pidgeon G, Maher S. MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. J Mol Med (Berl). 2012; 90(12):1449-58.
81. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, et al. MicroRNAs as Potential Agents to Alter Resistance to Cytotoxic Anticancer Therapy. Cancer Research. 2007; 67(23):11111-6.